Baird Maintains Outperform on Exact Sciences, Raises Price Target to $121
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Schulte maintains an Outperform rating on Exact Sciences (NASDAQ:EXAS) and raises the price target from $99 to $121.
August 04, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Catherine Schulte maintains an Outperform rating on Exact Sciences and raises the price target from $99 to $121.
The raised price target by Baird analyst Catherine Schulte indicates a positive outlook for Exact Sciences. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100